US Stock MarketDetailed Quotes
BCTX BriaCell Therapeutics
- 0.640
- -0.460-41.85%
Trading Dec 12 15:44 ET
23.54MMarket Cap-2.21P/E (TTM)
0.710High0.600Low7.66MVolume0.690Open1.100Pre Close5.03MTurnover23.52%Turnover RatioLossP/E (Static)36.80MShares5.97052wk High-9.84P/B20.82MFloat Cap0.46452wk Low--Dividend TTM32.55MShs Float12.470Historical High--Div YieldTTM9.99%Amplitude0.464Historical Low0.657Avg Price1Lot Size
BriaCell Therapeutics Stock Forum
Sign in to post a comment
$BriaCell Therapeutics (BCTX.US)$ Bearish news - Offering but no bad news about the company. Low risk, big reward potential imo. My SL below 0.50.
1
2
$BriaCell Therapeutics (BCTX.US)$ Reuters· 2 mins ago
Briacell Therapeutics Announces Proposed Public Offering
Briacell Therapeutics Announces Proposed Public Offering
2
19
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$BriaCell Therapeutics (BCTX.US)$
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Wednesday, 11th December at 7:50 am
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting...
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Wednesday, 11th December at 7:50 am
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting...
$BriaCell Therapeutics (BCTX.US)$ Pending good news leak out ?
1
$BriaCell Therapeutics (BCTX.US)$ The Data Safety Monitoring Board Has Completed Its First Review Of Safety Events In Patients Enrolled In BriaCell Therapeutics' Phase 3 Study Of Bria-IMT Plus An Immune Checkpoint Inhibitor, Recommending Continuation Of The Study In Metastatic Breast Cancer Patients
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT plus ...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT plus ...
2
1
$BriaCell Therapeutics (BCTX.US)$
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
Monday, 2nd December at 7:50 am
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune check point inhibitor in metastatic breast cancer
The pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration ...
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
Monday, 2nd December at 7:50 am
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune check point inhibitor in metastatic breast cancer
The pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration ...
$BriaCell Therapeutics (BCTX.US)$
Something brewing ?
Something brewing ?
1
1
$BriaCell Therapeutics (BCTX.US)$
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
SABCS® "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes
Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median overall survival calcula...
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
SABCS® "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes
Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median overall survival calcula...
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
LeadByAnimals : Same thoughts here
LeadByAnimals : Swing play hopefully